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Abstract
OBJECTIVES—To evaluate in a large, nationally representative cohort the association between 
high serum transferrin saturation (TS) and hospital length of stay and mortality in older adults.
DESIGN—Prospective cohort.
SETTING—Longitudinal analyses of the Third National Health and Nutrition Examination 
Survey linked to Medicare claims from 1991 through 2006.
PARTICIPANTS—Medicare beneficiaries aged 65 and older at baseline.
MEASUREMENTS—Transferrin saturation collected on each participant at baseline was 
characterized as <20.0%, 20.0% to 54.9%, and 55.0% and greater. Length of stay in the hospital 
and death in the hospital were primary outcomes. Analyses were adjusted for age, sex, race and 
ethnicity, education, and severity of illness.
RESULTS—Individuals hospitalized during the study period (79.4%) with high (odds ratio (OR) 
= 2.54, 95% confidence interval (CI) = 1.05–6.12) or low (OR = 1.31, 95% CI = 1.07–1.62) TS 
had a significantly greater risk of death than those with moderate TS. Individuals with high TS had 
longer average length of stay per hospitalization (11.1 days, (standard error, SE 1.7 days), P = .01) 
than those with moderate TS (8.4 (0.3) days). Individuals with high TS also had more hospital 
days per year (8.6 (2.0) days, P = .04) than those with moderate TS (6.7 (0.5) days).
CONCLUSION—High TS is associated with longer length of stay and death in the hospital 
(unweighted N = 3,847, weighted N = 28,395,464).
Keywords
transferrin saturation; National Health and Nutrition Examination Survey; Medicare; mortality
© 2012, Copyright the Authors© 2012, The American Geriatrics Society
Address correspondence to Arch G. Mainous III, Department of Family Medicine, Medical University of South Carolina, 295 Calhoun 
St., Charleston, SC 29425. mainouag@musc.edu.
Author Contributions: All authors contributed significantly to this work. All authors drafted and reviewed the subsequent versions of 
the manuscript and approved the final version.
Conflict of Interest: There are no potential conflicts of interest for any author. The authors declare no competing financial interests.
HHS Public Access
Author manuscript
J Am Geriatr Soc. Author manuscript; available in PMC 2015 June 16.
Published in final edited form as:













Serum transferrin saturation (TS) is a commonly used first-step measure in detecting 
hereditary iron overload in clinical practice and is recommended strategy in several 
guidelines.1–5 Evidence from large longitudinal cohort studies in the general population 
shows that high TS saturation is associated with greater risk of morbidity, from cancer for 
example, and all-cause mortality.6–8 A recent meta-analysis of general population studies 
supported the greater mortality risk associated with high levels of TS.9
In contrast, several studies have not found a link between high TS levels and mortality.10,11 
Initial steps in screening for hemochromatosis or iron overload is based on high TS is 
recommended based on TS greater than 45%, a level found in approximately 6% of the adult 
U.S. population.12,13 It is likely in the studies that did not find an effect that their results 
were due to categorization of their high group according to sample quartiles or quintiles, 
placing many individuals with normal TS into those studies’ high group (e.g., TS >29% in 
postmenopausal women would be considered high) and decreasing the likelihood of 
observing an effect of high TS.10,11 Many people are not evaluated for high TS and are 
therefore not diagnosed, even though detection and treatment are easy and inexpensive.12–14
It is unclear whether these deleterious effects of high TS seen with the development of 
disease or mortality affect hospital length of stay, particularly in older adults. Length of stay 
and mortality in the hospital are important outcomes for older adults.15 These factors are 
important for a variety of reasons, including healthcare use, and economic burden.15 
Consequently, the purpose of this study was to evaluate, in a large, nationally representative 
cohort, the association between high serum TS and hospital length of stay and mortality in 
Medicare beneficiaries aged 65 and older.
METHODS
Longitudinal analyses were conducted using data from the third National Health and 
Nutrition Examination Survey (NHANES III) linked to Medicare claims from 1991 through 
2006.16 NHANES III provides population estimates of the United States and was conducted 
from October 1988 through October 1994. It used complex, multistage, stratified, clustered 
samples of civilian, noninstitutionalized populations. Thirty thousand eight hundred eighteen 
persons were examined in mobile examination centers (MECs) that visited 89 communities 
across the United States. The cohort for the current study consisted of all persons aged 65 
and older at the time of their MEC visit. The health examination included collection of 
blood and urine specimens for various laboratory analyses.
Risk of hospitalization, death in the hospital, and hospital length of stay variables were 
investigated using the NHANES III data linked with Centers for Medicare and Medicaid 
Services (CMS) Medicare enrollment and claims files. Because of confidentiality concerns 
associated with this data, the National Center for Health Statistics (NCHS) Research Data 
Center linked the data and supplied it for analysis. Records from January 1, 1991, through 
December 31, 2006, were used. Death certificate data found in the National Death Index 
(NDI) that had been linked to the NHANES III data were also used. The NCHS Research 
Data Center merged the NDI data with the other files. The National Center for Health 
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Statistics has had good success merging data sets like the NDI with the NHANES, with 
evidence of a greater than 98% match.17
Although CMS data were available through December 31, 2007, NDI data were available 
only through December 31, 2006, so December 31, 2006, was used as the end of the study 
period. The time period of interest was from January 1, 1991, or the date of the MEC visit if 
it was later, through the date the subject joined a health maintenance organization (HMO) 
after which they had no more claims in the CMS data, died, or the end of the study period 
(December 31, 2006).
The Medical University of South Carolina institutional review board approved this project.
Transferrin Saturation
Serum iron and total iron-binding capacity (TIBC) were measured in serum, and was TS 
calculated by dividing serum iron by TIBC and multiplying by 100. TS was categorized as 
less than 20.0%, 20.0% to 54.9%, and 55.0% or greater. Although there is not universal 
agreement on the upper and lower limits of normal TS, these cut points correspond to 
several conventional standards.18 Moreover, previous studies of TS and mortality risk found 
an association between mortality and TS at TS levels of 55% or higher.6 The middle 
category was used as the reference in each analysis.
Covariates
Covariates used in the analyses were age at baseline in NHANES III, sex, race and ethnicity 
(non-Hispanic white, non-Hispanic black, Hispanic, and other), education (<12th grade, high 
school, and >high school), and severity of illness as measured according to the Charlson 
Comorbidity Index,19 a commonly used measure of severity of illness, includes 1 point each 
for heart attack, congestive heart failure, stroke, chronic bronchitis or emphysema, lupus, 
diagnosed or undiagnosed diabetes mellitus (glycohemoglobin > 6.5%),20 ulcer, and liver 
disease (high alanine aminotransferase (ALT) or aspartate aminotransferase (AST)). AST 
greater than 37 U/L or ALT greater than 40 U/L in men, or AST greater than 31 U/L or ALT 
greater than 31 U/L in women indicated liver disease.21 Also included with 2 points each 
were cancer (other than skin cancer), diabetic retinopathy, paralysis in hands or legs, 
leukemia, lymphoma, and renal disease (urinary albumin to urinary creatinine ratio > 30).22
Outcomes
Variables evaluated were hospitalization, death in the hospital, average length of stay per 
hospitalization, average number of hospital days per year, and average number of hospital 
stays per year. Although the NDI is not limited to documenting death in the hospital, this 
study was limited to death in the hospital.
Analysis
The relationship between sex and other demographic variables was first evaluated using chi-
square analysis. Whether a subject had ever stayed in the hospital and time to the first 
hospitalization were analyzed based on Medicare Provider Analysis and Review 
(MEDPAR) records.23 Risk of hospitalization was tested using a survival analysis adjusted 
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for age, sex, race and ethnicity, education, and Charlson Comorbidity Index. Survival 
analysis was used for this test because persons who joined an HMO might have had a 
different length of time available for follow-up than those who had claims data throughout 
the study period.
In individuals who were hospitalized, death in the hospital was then investigated also based 
on MEDPAR records. Risk of death in the hospital was evaluated in a logistic regression 
adjusted for the same covariates as the survival analysis for risk of hospitalization. Logistic 
regression was chosen rather than a proportional hazards model for risk of death within the 
hospital because the analysis was limited to people who had been hospitalized. The length of 
stay variables (length of stay in a hospital, hospital days per year, and number of hospital 
stays) were further evaluated in individuals who did not die in the hospital using predicted 
marginals in linear regressions adjusted for the aforementioned set of covariates. Predicted 
marginals are a generalization of adjusted means and were used to represent adjusted 
means.24 Average length of stay was derived from these numbers. Those unlogged values 
are presented for context. This variable was transformed using the natural log of length of 
stay because of the nonnormal distribution of length of stay, and this was used for the actual 
significance test. The average number of hospitalized days per year was also computed 
based on the total number of days in the hospital divided by the total number of years of 
follow-up in the study period. This measure was also log transformed.
The average number of hospital stays per year was computed. Number of stays was not log 
transformed for analysis because its distribution more closely resembled a normal 
distribution. These analyses were adjusted for the aforementioned set of covariates.
All analyses were performed using SUDAAN (SUDAAN Statistical Software Center, 
Research Triangle Park, NC), and the appropriate weighting and design variables were used 
to generate population estimates for the United States.
RESULTS
Demographic characteristics of the cohorts are shown in Table 1. A total of 1.2% of the 
cohort had TS greater than 55%. The unweighted N was 3,847, with a population estimate of 
28,395,000. The proportion of participants hospitalized during the study period was 79.4%. 
The primary diagnoses for hospitalization episodes for each of three TS groups are presented 
in Table 2. Based on the three-digit stem for International Classification of Diseases, Ninth 
Revision, codes, there was a high degree of similarity between the groups, with heart failure, 
pneumonia, and other cardiac disease being present in all groups.
The survival analysis for risk of future hospitalization indicated no difference between 
persons with TS of 55.0% or greater (hazard ratio (HR) = 0.86, 95% confidence interval (CI) 
0.60–1.23) or TS less than 20.0% (HR = 1.04, 95% CI 0.92–1.17) and those in the reference 
category of moderate levels of TS (20.0–54.9%).
When the analysis was reduced to individuals who were hospitalized, the logistic regression 
for death in the hospital showed that individuals with high or low TS had a significantly 
greater risk of death than the reference category of those with moderate TS (Table 3). In 
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terms of the proportion of individuals dying in the hospital in each group, 51.7% of those 
with TS of 55.0% or greater, 27.9% of those with TS from 20.0% to 54.9%, and 34.7% of 
those with TS less than 20.0% died in the hospital. The analysis had a mean of 7.4 years of 
follow-up to death. Table 4 indicates that the average length of stay per hospitalization and 
average hospital days per year were significantly higher in subjects with TS of 55.0% or 
greater than in those in the moderate TS group.
DISCUSSION
The results of this investigation indicate that high TS is associated with greater risk of death 
in the hospital, longer length of stay per episode, and more hospital days per year. This 
effect was present after controlling for age, sex, race, severity of illness, and access to care. 
These results are consistent with previous findings describing other risks associated with 
high TS, such as all-cause mortality and disease development when TS is 55.0% or greater. 
Together, these findings suggest that high TS is a marker of underlying physiological 
changes that increase the risk of morbidity and mortality.6–9 High TS was not associated 
with more hospital stays per year. Further studies are needed to evaluate whether 
interventions to decrease TS could have a physiological effect and thus improve these health 
outcomes.
Although only 1.2% of these Medicare beneficiaries had high TS, they accounted for more 
than 341,000 individuals who are at greater risk for longer lengths of stay in the hospital, 
more hospitalized days per year, and death in the hospital. This group of Medicare 
beneficiaries receives public financing of their health care, so the additional costs due to 
more hospitalized days is passed on to the federal government and the taxpayer. Because 
high TS is easily detectable and treated, this question of Medicare spending due to a 
potentially preventable cause is particularly germane in a time when the federal budget 
deficit is high. These results also indicate that the types of diagnoses for which individuals 
with high TS are hospitalized are similar to those of other individuals with normal TS, 
suggesting that diagnosis upon hospitalization may not suggest further need for investigation 
into high TS by healthcare providers. More-aggressive screening and detection of high TS 
may be warranted.
A possible mechanism for why high TS could result in poor outcomes even after accounting 
for factors such as severity of illness could be because high TS is associated with oxidative 
stress.25 High TS is also associated with cellular toxicity.25 This general mechanism has 
implications for worse outcomes across a variety of diseases and organ systems.26,27
In addition to the finding that high TS is associated with greater risk of death in the hospital 
and longer length of stay, low TS was also associated with greater risk of death and more 
days in the hospital. It is unclear why low TS would be associated with these outcomes, but 
it is possible that these low levels of TS represent iron deficiency, a condition associated 
with morbidity.28 Iron-deficiency anemia is associated with low TS, low serum ferritin, and 
low hemoglobin and is a common hematological abnormality in older individuals that is 
associated with morbidity.29,30 Adequate iron stores are also necessary for several 
nonerythropoietic biologic processes such as preservation of immune function, 
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thermoregulation, and cognition. Impairment of these processes due to low TS could lead to 
greater mortality.
There are several strengths of this study. First, it used a nationally representative cohort in 
whom the independent variable of TS and measures needed to compute severity of illness 
(e.g., glycohemoglobin for undiagnosed diabetes mellitus, liver function tests, albumin 
creatinine ratio) were collected according to a standardized protocol. This methodology is 
less likely to result in measurement bias than studies using only self-reports or data that may 
have been inconsistently collected in electronic health records. Second, the study used a 
population of Medicare beneficiaries. This is particularly important because lack of 
insurance has been shown to have a significant effect on hospital length of stay.31,32
One limitation of this study was the small percentage of persons with high TS (≥ 55.0%), 
which allowed reliable estimates for the most general outcomes but limited the ability to 
perform several other analyses. The significant findings in spite of the small number of 
persons in this category for a variety of hospitalization outcomes including death in the 
hospital, average length of stay per hospitalization, and average number of days in the 
hospital per year provide evidence of a strong effect of this measure of iron stores. Members 
of the cohort who joined an HMO before the end of the study further limited the number of 
subjects for follow-up because no claims data from this source of care were available for 
analysis. Furthermore, the CMS data covered care beginning in January 1, 1991, which 
meant that persons whose MEC visit was in 1988–1990 had missing data for hospitalizations 
that occurred between their MEC visit and this date, but because NDI mortality data were 
available for 1988–1990, information regarding their vital status during this period was 
available.
In conclusion, high TS is associated with greater mortality during hospitalizations and 
longer length of stay. Further studies to evaluate the clinical significance of these findings 
and develop possible interventions are needed.
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Table 1
Baseline Demographic Characteristics of the Third National Health and Nutrition Examination Survey–
Medicare Linked Cohort
Characteristic Total Men Women P-Value
Unweighted (N) 3,847 1,867 1,980
Population estimate, n (%) 28,395,464 12,134,729 (42.7) 16,260,735 (57.3)
Age,%
 65–74 61.4 66.6 57.6 <.001








 Hispanic 4.2 4.4 4.1
 Other 1.6 1.5 1.6
Education,%
 <12th grade 43.5 45.5 42.1 <.001
 High school 28.9 24.1 32.6
 >High school 27.5 30.4 25.4
Charlson Comorbidity Index
 0 45.0 42.1 47.1 .069
 1 18.7 21.0 17.0
 >2 36.3 36.9 35.9
Transferrin saturation,%
 ≥55.0 1.2 1.5 1.0 <.001
 20.0–54.9 67.0 74.3 61.6
 <20.0 31.7 24.2 37.4
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Table 2
Most Frequent Primary Diagnoses for Hospitalization Episodes According to TS Level
≥55.0% 20.0–54.9% <20.0%
Diagnosis (International Classification of Diseases, Ninth Revision, code)
 Ischemic heart
 disease (414)
Heart failure (428) Heart failure (428)
Acute myocardial
 infarction (410)
Pneumonia (486) Pneumonia (486)
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Table 3








Adjusted for age at baseline, sex, race and ethnicity, education, and Charlson Comorbidity Index.
Reference 20.0–54.9%.
Unweighted N = 3,048; weighted N = 22,559,000.
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Table 4
Hospital Length of Stay Characteristics According to Transferrin Saturation Percentage Excluding Individuals 





Average length of stay per hospitalization
 ≥55.0 11.11 (±1.73) .01
 20.0–54.9 8.45 (±0.31) Reference
 <20.0 9.66 (±0.77) .173
Average hospital days per year
 ≥55.0 8.56 (±2.00) .04
 20.0–54.9 6.70 (±0.47) Reference
 <20.0 9.73 (±1.37) .01
Average number of stays per year
 ≥55.0 0.78 (±0.20) .50
 20.0–54.9 0.64 (±0.04) Reference
 <20.0 0.80 (±0.06) .006
Adjusted for age at baseline, sex, race and ethnicity, education, and Charlson Comorbidity Index.
Unweighted N = 2,019; weighted N = 15,709,000.
a
P-value based on difference in 1 n (days).
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